Global X HealthTech ETF (HEAL)

Restart Life Sciences Leverages University of Manitoba RCFTR Collaboration for Pre-Production Transition of New Protein Frameworks

Restart Life Sciences Details Next-Generation Product Pipeline and Segment Expansion for Holy Crap

Restart Life Sciences Reports Record-Breaking June Revenue for Holy Crap Foods as Amazon Canada Sales Surge YoY

Restart Life Advances AI-Driven E-Commerce Strategy to Scale Online Sales Growth for Holy Crap Foods

Restart Life Subsidiary Holy Crap Foods Marks New International Expansion Milestone with Bahamas On-Demand App Launch

Restart Life Sciences Appoints Inez Ho as Chief Financial Officer

Restart Life Sciences Closes Dedicated Purchase Order Financing Private Placement; CEO Subscribes for 50% of Offering

Medicine's Not Going Anywhere: 3 of the Most Resilient Healthcare ETFs

Restart Life Sciences Advances New Product Relaunch Utilizing Acquired Intellectual Property Portfolio

Restart Life Sciences Leverages Amazon Logistics for Strategic Entry of Holy Crap Foods into U.S. Market

Restart Life Sciences Announces Dedicated Purchase Order Financing Through Private Placement Offering

Restart Life Sciences Strengthens Operational Infrastructure to Scale "Better-for-You" Portfolio

Restart Life Sciences Reports Holy Crap Foods Revenue Gains of 46% in Wholesale and 32% via Amazon Channels YoY

Restart Life Advances Holy Crap Growth Strategy with New Protein SKU Nearing Commercialization

Restart Life Sciences' Wholly Owned Subsidiary Holy Crap Foods Reports over 500,000 Units Sold, Highlighting Strong Consumer Adoption

Restart Life Sciences Provides Performance and Revenue Trend Update on Newly Acquired Superseed Cereals and Oatmeal Brand Portfolio